- Home
- ALT
ALT
Altimmune Inc.
as of 03-06-2026 3:56pm EST
$3.55
+$0.04
+1.00%
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 415.3M | IPO Year: | 2005 |
| Target Price: | $16.00 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.00 | EPS Growth: | 25.37 |
| 52 Week Low/High: | $2.91 - $7.73 | Next Earning Date: | 06-10-2026 |
| Revenue: | $41,000 | Revenue Growth: | 105.00% |
| Revenue Growth (this year): | -89.21% | Revenue Growth (next year): | 756308.50% |
| P/E Ratio: | -4.76 | Index: | N/A |
| Free Cash Flow: | -67546000.0 | FCF Growth: | N/A |
AI-Powered ALT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.54%
76.54%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Altimmune Inc. (ALT)
Pisano Wayne
Buy
Director
ALT Jan 8, 2026
Avg Cost/Share
$4.08
Shares
5,000
Total Value
$20,410.00
Owned After
13,498
SEC Form 4
Sohn Catherine A.
Buy
Director
ALT Jan 5, 2026
Avg Cost/Share
$4.24
Shares
500
Total Value
$2,117.55
Owned After
1,500
SEC Form 4
Jorkasky Diane
Buy
Director
ALT Dec 29, 2025
Avg Cost/Share
$3.80
Shares
527
Total Value
$2,002.60
Owned After
527
SEC Form 4
Durso Jerome Benedict
Buy
Director
ALT Dec 22, 2025
Avg Cost/Share
$4.13
Shares
12,500
Total Value
$51,568.75
Owned After
12,500
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Pisano Wayne | ALT | Director | Jan 8, 2026 | Buy | $4.08 | 5,000 | $20,410.00 | 13,498 | |
| Sohn Catherine A. | ALT | Director | Jan 5, 2026 | Buy | $4.24 | 500 | $2,117.55 | 1,500 | |
| Jorkasky Diane | ALT | Director | Dec 29, 2025 | Buy | $3.80 | 527 | $2,002.60 | 527 | |
| GILL JOHN | ALT | Director | Dec 23, 2025 | Buy | $4.10 | 12,500 | $51,250.00 | 12,500 | |
| Durso Jerome Benedict | ALT | Director | Dec 22, 2025 | Buy | $4.13 | 12,500 | $51,568.75 | 12,500 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Mar 5, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYMar 5, 2026 · 100% conf.
AI Prediction BUY
1D
+7.25%
$4.58
5D
+8.80%
$4.65
20D
+10.73%
$4.73
Price: $4.28 Prob +5D: 100% AUC: 1.000
0001326190-26-000013
ALTIMMUNE, INC._March 5, 2026 0001326190false00013261902026-03-052026-03-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026
ALTIMMUNE, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-32587
20-2726770
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number including area code: (240) 654-1450 (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.0001 per share ALT The NASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On March 5, 2026, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fourth quarter and full year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference into such filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits
No. Description
99.1 Press Release of Altimmune, Inc. dated March 5, 2026
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALTIMMUNE, INC.
By:
/s/ Gregory Weaver
Name: Gregory Weaver
Title: Chief Financial Officer
Dated: March 5, 2026
2025 Q3 Q3 2025 Earnings
8-K BUY Nov 6, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K BUYNov 6, 2025 · 100% conf.
AI Prediction BUY
1D
+7.84%
$4.25
5D
+9.95%
$4.33
20D
+6.28%
$4.19
Price: $3.94 Prob +5D: 100% AUC: 1.000
0001326190-25-000055
ALTIMMUNE, INC._November 6, 2025 0001326190false00013261902025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025
ALTIMMUNE, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-32587
20-2726770
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number including area code: (240) 654-1450 (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.0001 per share ALT The NASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement On November 5, 2025, (the “Amendment Closing”), Altimmune, Inc. (the “Company”) entered into an amendment to the Loan and Security Agreement with Hercules Capital, Inc. (“Hercules”) and the lenders party thereto, pursuant to which the lenders will make available up to four tranches of term loans (the “Term Loan”), subject to certain terms and conditions (the “Amendment”). The Amendment modified that certain Loan and Security Agreement, dated as of May 13, 2025, by and between the Company and Hercules. Under the terms of the Amendment, the lenders will, among other things, increase the availability under the Term Loan from an aggregate principal amount of $100.0 million to $125.0 million. The first Term Loan tranche was drawn down at closing on May 13, 2025 in an aggregate principal amount of $15.0 million. The second Term Loan tranche was drawn down upon the Amendment Closing in an aggregate principal amount of $20.0 million. Upon the achievement of certain milestones and subject to other terms and conditions set out in the Loan Agreement, as amended, the third Term Loan tranche will be made available in an aggregate principal amount of up to $10.0 million. The fourth Term Loan tranche will be made available in an aggregate principal amount of up to $80.0 million subject to the approval of the lenders. The Term Loan, as amended, bears interest equal to the greater of (a) 9.70% per annum and (b) the prime rate as reported in The Wall Street Journal plus 2.45% per annum. The interest-only period has been extended to 30 months from May 13, 2025. The foregoing description of the amended agreement is not complete and is qualified in its entirety by reference to the full text of the agreement, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 2.02 Results of Operations and Financial Condition On November 6, 2025, the Company issued a press release announcing the Company’s financial results for its third quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any gen
2025 Q2 Q2 2025 Earnings
8-K Aug 12, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 12, 2025
0001558370-25-011145
0001326190false00013261902025-08-122025-08-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025
ALTIMMUNE, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-32587
20-2726770
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number including area code: (240) 654-1450 (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.0001 per share ALT The NASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On August 12, 2025, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its second quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference into such filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits
No.
Description
99.1 Press Release of Altimmune, Inc. dated August 12, 2025
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALTIMMUNE, INC.
By:
/s/ Gregory Weaver
Name: Gregory Weaver
Title: Chief Financial Officer
Dated: August 12, 2025
Latest Altimmune Inc. News
ALT Breaking Stock News: Dive into ALT Ticker-Specific Updates for Smart Investing
Compare ALT vs Leading Stocks
See how ALT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ALT Altimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.